1535P Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Scheck, M., Goetze, T.O., Ettrich, T.J., Schmalenberg, H., Clemens, M.R., Mahlberg, R.J.C., Heeg, S., Kanzler, S., Hapke, G., Thuss-Patience, P.C., Kestler, A., Treschl, A., Frost, G.A., Heidel, S., Schiemer, M., Junge, S., Pauligk, C., Al-Batran, S-E., Lorenzen, S.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article